Phase I/Ib Study of the PARP Inhibitor Olaparib (O) with Carboplatin (C) in BRCA1/2 Mutation Carriers with Breast or Ovarian Cancer (br/ovca) (NCT00647062).
Journal of Clinical Oncology（2013）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined